منابع مشابه
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
The development of anticoagulants for treating patients with atherothrombotic disorders of the arterial circulatory system has focused, either directly or indirectly, on thrombin - a pleuripotential effector enzyme with prothrombotic and proinflammatory properties. The pivotal role of factor (f) Xa in thrombin generation, coupled with its direct cellular effects and widely recognized limitation...
متن کاملAntithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin.
BACKGROUND Recent evidence suggests that TF may play a causal role in acute coronary syndromes, and may be an important therapeutic target. Several inhibitors of TF, coagulation factors VIIa and Xa are under investigation as novel antithrombotic approaches. We compared the antithrombotic effects of DX-9065a, a new FXa inhibitor, vs. enoxaparin. METHODS AND RESULTS The protocol was an open-lab...
متن کاملInhibitor (DX-9065a): Implications for Interventional Use
Heparin has been conventionally used as an anticoagulant for medical and surgical indications. Because factor Xa is an essential component of the prothrombinase complex and leads to the generation of thrombin, its inhibition has become a focus of newer antithrombotic drug development. The in vitro anticoagulant profile of DX-9065a, a synthetic direct factor Xa inhibitor, was studied using activ...
متن کاملCombined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.
Dear Sir, The development of novel anticoagulants for use in patients with acute coronary syndromes (ACS) has evolved steadily, emphasizing the importance of cellular surface biochemistry and the highly integrated contribution of platelets, leukocytes and endothelial cells in the thrombotic process. Accordingly, tissue factor and its primary complexing coagulation proteases, factor VIIa and Xa,...
متن کاملA New Oral Direct Factor Xa Inhibitor
Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic events (VTE). Factor Xa is an attractive target for anticoagulant treatment, as it is the primary and rate-limiting source of amplification in th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cardiovascular Drug Reviews
سال: 2006
ISSN: 0897-5957
DOI: 10.1111/j.1527-3466.2003.tb00108.x